Not Signed In -
Warts, Genital |
Anal Warts |
Clinical Trial: Study of an Investigational Vaccine in Pre-Adolescents and Adolescents
This study is no longer recruiting patients.
|
Purpose
The primary purpose of the study is to determine if an investigational vaccine with 4 components will provide an immune response and will be well tolerated in pre-adolescents and adolescents.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Cervical Cancer Genital Warts | Vaccine: Investigational Vaccine | Phase II Phase III |
MedlinePlus related topics: Cervical Cancer; HPV; Sexually Transmitted Diseases
Study Type: Interventional
Study Design: Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment
Official Title: A Study to Determine the Immunogenicity and Tolerability of an Investigational Vaccine in Pre-Adolescents and
Eligibility
Ages Eligible for Study: 10 Years - 23 Years, Genders Eligible for Study: Both
Accepts Healthy Volunteers
Criteria
Inclusion Criteria:
- Healthy adolescents and pre-adolescents with no prior sexual history
- Healthy women who have an intact uterus with lifetime history of 0-4 sexual partners
Exclusion Criteria:
- Prior Human Papillomavirus (HPV) vaccination
- Prior abnormal Paps
- Prior history of gential warts
Location Information
Pennsylvania
Call for Information, Horsham, Pennsylvania, 19044, United States
More Information
Study ID Numbers: 2004_083
Record last reviewed: September 2004
Last Updated: October 13, 2004
Record first received: September 22, 2004
ClinicalTrials.gov Identifier: NCT00092495
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Record last reviewed: September 2004
Last Updated: October 13, 2004
Record first received: September 22, 2004
ClinicalTrials.gov Identifier: NCT00092495
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
email this page
print this page
bookmark this page
feedback on this page
